coteau ARQ.

ELOX

Eloxx Pharmaceuticals, Inc.
$12.80
−$0.32 (2.44%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-2%+21%+44%+68%+91%Jun 9Oct 23Aug 16
ELOXSPY
Wall St. Highest PT $43.00 (+235.9%) Wall St. Avg PT $38.25 (+198.8%)
$11$23$34$46$58POC $12Hi $43Avg $38
Underwater Drawdown %Max DD -41.8%Current -39.0%
0.0%-41.8%
Relative Strength vs SPY+12.6% vs SPYOutperforming
+99%0%-99%
1W
−$0.23 (1.77%)
1M
−$2.64 (17.10%)
3M
+$0.86 (7.20%)
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
4 analysts · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$12.80
Average target$38.25
+$25.45 (+198.8%) upsideaverage target vs current price
CurrentAverageMedian
Low$32.00
Median$38.25
High$43.00
12-month Wall Street target range
Recent analyst rating changes · 8
Initiated
2026-10-15 · Cantor Fitzgerald started covering ELOX at Overweight
Initiated
2026-09-18 · Leerink Partners started covering ELOX at Outperform
Reiterated
2026-08-24 · Guggenheim reiterated Buy on ELOX
Initiated
2026-08-20 · LUCID CAPITAL MARKETS started covering ELOX at Buy
Initiated
2026-07-22 · LifeSci Capital started covering ELOX at Outperform
Initiated
2026-07-20 · Guggenheim started covering ELOX at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$51.7M
P/E (last 12 months)3.6
P/E (next 12 months, estimated)-18.0
52-week range$8.20 – $23.40
Dividend yieldNo dividend
Analyst consensusStrong Buy (4)
Average analyst price target$38.25 (+199%)

What they do

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ELOX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

ELOX earningsNo upcoming date on file
Last 4 quarters · EPS vs estimate
Nov 13, 2023-$14.41est -$21.67+33.5%Above estimates
Aug 11, 2023-$21.56est -$16.94−27.3%Below estimates
May 12, 2023-$31.68est -$28.05−12.9%Below estimates
Mar 31, 2023-$33.55est -$32.67−2.7%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 03:04:39 ET
22-0322-0522-0822-1123-0323-0523-0823-11-57.200.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
Eloxx Pharmaceuticals Finalizes 52-Week Phase 2 EXPRESS Study Design in Nonsense-Mutation ADPKD and Appoints T.R. Srinivas, M.D., Chief Medical Officer
PR Newswire · Oct 20
Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
PR Newswire · Oct 19
Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome
PR Newswire · Sep 11
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
PR Newswire · Aug 12
Rating changes
Initiated
2026-10-15 · Cantor Fitzgerald started covering ELOX at Overweight
Initiated
2026-09-18 · Leerink Partners started covering ELOX at Outperform
Reiterated
2026-08-24 · Guggenheim reiterated Buy on ELOX
Initiated
2026-08-20 · LUCID CAPITAL MARKETS started covering ELOX at Buy
Initiated
2026-07-22 · LifeSci Capital started covering ELOX at Outperform
Initiated
2026-07-20 · Guggenheim started covering ELOX at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 03:04:39 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026